StockWatch
·

AARTI DRUGS LTD. Q2 FY27 Results

AARTIDRUGSQ2 FY27 Results
Filing
Result:Good· Market: Down#Margin expansion
MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue706.2812.6%22.0%
Total Income708.9312.9%22.4%
Expenditure632.2013.4%20.8%
PBT76.7313.1%37.6%
Net Profit57.6813.4%38.1%
OPM13.82%0.49pp0.83pp
NPM8.14%0.04pp0.93pp
EPS6.3213.5%38.0%
View full financials

Pharma: revenue grew a modest 8.2% but adjusted PAT rose 27.7% on genuine margin expansion (OPM 12.9%→13.8%, NPM 6.9%→8.1%), a healthy above-average quarter but not a standout given muted top-line growth.

Aarti Drugs Q2 FY27 Revenue ₹828.8 Cr, PAT ₹82.8 Cr

03 Nov 2026 · 3 Nov, 9:21 pm

Summary

Aarti Drugs Limited reported a landmark Q2 FY27 with total revenue reaching Rs. 828.8 crore, a 27% year-over-year increase, and EBITDA soaring by 63% YoY to Rs. 137.9 crore. Profit After Tax (PAT) also saw a substantial 83% YoY jump to Rs. 82.8 crore, with PAT margins expanding to 10.0%. For the first half of FY27, revenue grew 23% YoY to Rs. 1,532.4 crore and EBITDA by 48% YoY to Rs. 234.8 crore. Management highlighted broad-based growth across businesses, with the Specialty Chemicals segment nearly doubling and the Formulations business growing 58%, attributing the strong performance to volume growth, favorable realisations, and increased integration.

Key Highlights

  1. 1

    Total Revenue for Q2 FY27 stood at Rs. 828.8 crore, marking a significant 27% year-over-year growth compared to Rs. 652.9 crore in Q2 FY26.

  2. 2

    EBITDA for the second quarter of FY27 reached Rs. 137.9 crore, an impressive increase of 63% YoY from Rs. 84.4 crore in Q2 FY26.

  3. 3

    Profit After Tax (PAT) for Q2 FY27 more than doubled to Rs. 82.8 crore, an 83% surge from Rs. 45.2 crore in the prior year period.

  4. 4

    Revenue for the first half of FY27 grew by 23% YoY to Rs. 1,532.4 crore, up from Rs. 1,243.7 crore in H1 FY26.

  5. 5

    EBITDA for H1 FY27 increased by 48% YoY to Rs. 234.8 crore, compared to Rs. 158.8 crore in H1 FY26.

  6. 6

    PAT for H1 FY27 rose by 34% YoY to Rs. 132.9 crore, up from Rs. 99.1 crore in H1 FY26.

  7. 7

    The Specialty Chemicals business nearly doubled in Q2 FY27 with 92% YoY growth, driven by the scale-up of the Sayakha facility.

Management Comments

A

Adhish Patil

Q2 FY27 has been a landmark quarter for Aarti Drugs. We achieved our highest-ever revenue from operations of Rs. 826 crore and reported our highest-ever quarterly EBITDA of Rs. 138 crore. EBITDA margin expanded 370 basis points to 16.6%, the highest level in nearly six years. This performance reflects a combination of volume growth, strong realisations across our API, formulations and Specialty Chemicals portfolio, and the steady progress we have made in building a more integrated manufacturing platform. Through a period of considerable global volatility, all our facilities operated without disruption which enabled us to serve our customers reliably as their trusted partner. Growth during the quarter was broad-based across our businesses. Our Specialty Chemicals business nearly doubled as our Sayakha facility scaled up, and our Formulations business grew 58%, led by strong demand in export markets. Within a year of commissioning, Sayakha is meeting a significant share of our metformin intermediate requirements in-house, enhancing both our cost competitiveness and the security of our supply chain in the anti-diabetic segment. At the same time, our capacity expansions at Tarapur, Sarigam and Baddi, including new USFDA-compliant capacity, are progressing well and will deepen our presence in regulated markets. This period also marks an important moment in our leadership journey. Starting October 1" 2026, Mr. Prakash M. Patil retired as Chairman, Managing Director and CEO after a lifetime of dedicated service to the Company. His vision, integrity and leadership laid the foundations on which Aarti Drugs stands today, and on behalf of the Board and the entire Aarti Drugs family, | express our deepest gratitude to him. With Mr. Rashesh Gogri taking over as Chairman, and as | take charge as Managing Director, we remain committed to the values and long-term thinking that have guided the Company for decades. Looking ahead, we are building Aarti Drugs into a more integrated, more diversified and more globally relevant pharmaceutical company and aim to remain focused on improving capacity utilisation, expanding our regulatory footprint and creating sustainable growth for all our stakeholders.

Informational and educational content only. Not investment advice.